Table 2. Baseline characteristics.
| N | (%) | Mean(SD) | |
| Overall | 3506 | (100.0) | |
| Sex | 2105 | (60.0) | |
| Male | |||
| Female | 1401 | (40.0) | |
| Age (yrs) | 3498 | 62.8(11.9) | |
| BMI (kg/m2) | 3506 | 23.7(3.3) | |
| Weight (kg) | 3506 | 61.8(11.6) | |
| Duration of diabetes (yr) | |||
| <1 | 44 | (1.3) | |
| ≥1, <5 | 406 | (11.6) | |
| ≥5 | 2856 | (81.5) | |
| Unknown | 200 | (5.7) | |
| Number of pre-study OADs | |||
| One | 717 | (20.5) | |
| Two | 1434 | (40.9) | |
| Three | 1046 | (29.8) | |
| Four or more | 309 | (8.8) | |
| Pre-study OADs | |||
| Biguanides | 1665 | (47.5) | |
| Sulfonylureas | 3118 | (88.9) | |
| Glinides | 249 | (7.1) | |
| Alpha-glucosidase inhibitors | 1621 | (46.2) | |
| Thiazolidinediones | 1216 | (34.7) | |
| Neuropathy | 873 | (24.9) | |
| Retinopathy | 907 | (25.9) | |
| Nephropathy | 891 | (25.4) | |
| eGFR (mL/min/1.73 m2) | 503 | (14.3) | |
| <60 | |||
| ≥60, <90 | 1292 | (36.9) | |
| ≥90 | 875 | (25.0) | |
| Starting dose (U/kg/day) | 3506 | 0.100(0.056) | |
| Baseline HbA1c (%) | 3515 | 9.53(1.19) |